Biotech Values

[mcbio]

curious why you say it is a PI - from your link:

BL-8020 acts via a unique mechanism of action, by inhibiting hepatitis C virus-induced autophagy (cell degredation), which differs from the mechanism of currently used anti- hepatitis agents

sounds to me like it modifies host factors like the debiopharma compound NVS licensed

Initially, I shared your thoughts as well. But, I did a quick Google search and I believe I found genoscience's Web site at http://www.3dgenoscience.com/ . Although it admittedly appears to be a bit outdated, all their Web site refers to are HCV PIs. Perhaps their approach is some type of modification on a typical PI, but by and large it still sounds like this licensing deal is effectively for a PI. Perhaps this is an uber-secret PI like ACHN's ACH-2684 (I'm being facetious of course. See #msg-46028739. )